Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pantoprazole + doxorubicin hydrochloride
- Development stage
- Unknown
- Lead developer
- Princess Margaret Cancer Centre
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of the anthracycline chemotherapy agent doxorubicin hydrochloride and the proton pump inhibitor pantoprazole. This regimen was investigated in a Phase I dose-finding study led by the University Health Network and Princess Margaret Cancer Centre for patients with advanced solid tumors. Doxorubicin hydrochloride works by intercalating into DNA and inhibiting topoisomerase II, thereby preventing DNA replication and transcription. Pantoprazole, traditionally used to reduce gastric acid, was combined with doxorubicin to potentially enhance its antitumor activity by improving drug distribution within the acidic microenvironment of solid tumors and inhibiting autophagy, a mechanism associated with chemotherapy resistance.
- Brand names
- AdriamycinProtonix
- Other names
- pantoprazole sodium + doxorubicin hydrochloridepantoprazole + doxorubicindoxorubicin hydrochloride
02
Targets
TOP2A (DNA topoisomerase II)ATP4A (Potassium–transporting ATPase alpha chain 1)DNA
Beyond the preview
Go deeper on pantoprazole + doxorubicin hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pantoprazole + doxorubicin hydrochloride.